Xanodyne Pharmaceuticals Report issue

Contributed to NME For profit Phase 3 Phase 4
Founded: Newport KY United States (2000)
Status: Acquired by Assertio (2012)

Organization Overview

First Clinical Trial
2006
NCT00366444
First Marketed Drug
2000
propoxyphene (Darvon)
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Xanodyne | XANODYNE PHARM | XANODYNE PHARMS INC

Active Ingredients

Marketed Drugs (6)

acetaminophen (tylenol) (1972)

acetylsalicylic acid (aspirin) (1957)

caffeine (1957)

leucovorin (1980)

morphine (1991)

propoxyphene (Darvon) (1971 NDA)

Drugs in Phase 4 Trials (1)

propoxyphene (Darvon) (2 trials)

Drugs in Phase 3 Trials (2)

diclofenac (voltaren) (2 trials)

tranexamic acid (cyklokapron) (1 trial)

Indications

Approved Indications


 

Pain

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Pain (Phase 3)

Menorrhagia (Phase 3)

Pain, Postoperative (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 3